Rapport Therapeutics (RAPP) Set to Announce Quarterly Earnings on Thursday

Key Points

• Q3 2026 earnings are due before market open Thursday, November 5. Analysts expect Rapport Therapeutics to report a loss of $1.20 per share, following a $1.19-per-share loss that missed consensus in the prior quarter.
• RAPP shares opened at $22.50, near their 12-month low of $22.06 and well below the 12-month high of $52.93. Despite the decline, analysts maintain a consensus “Buy” rating with an average price target of $68.36.
• Analyst sentiment is mixed but includes several recent target increases, while insider activity has been mixed: executives sold shares in the past 90 days, but a director recently purchased 35,714 shares.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.20) per share for the quarter. Parties may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). On average, analysts expect Rapport Therapeutics to post ($4.08) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Rapport Therapeutics Price Performance

Shares of NASDAQ RAPP opened at $22.50 on Thursday. Rapport Therapeutics has a 12-month low of $22.06 and a 12-month high of $52.93. The company has a market capitalization of $1.08 billion, a PE ratio of -7.40 and a beta of 1.22. The firm's 50-day moving average is $37.66 and its two-hundred day moving average is $35.61.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on RAPP shares. JonesTrading raised their price objective on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a "buy" rating in a research note on Wednesday, October 21st. Wall Street Zen downgraded Rapport Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Guggenheim upped their target price on Rapport Therapeutics from $65.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, October 20th. Finally, BTIG Research increased their target price on Rapport Therapeutics from $75.00 to $89.00 and gave the company a "buy" rating in a report on Tuesday, October 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $68.36.

Insider Transactions at Rapport Therapeutics

In other Rapport Therapeutics news, COO Cheryl Gault sold 10,000 shares of the company's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total value of $331,900.00. Following the transaction, the chief operating officer directly owned 139,914 shares in the company, valued at approximately $4,643,745.66. This represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven M. Paul bought 35,714 shares of Rapport Therapeutics stock in a transaction on Thursday, October 22nd. The stock was purchased at an average price of $27.28 per share, for a total transaction of $974,277.92. Following the completion of the acquisition, the director owned 77,380 shares in the company, valued at $2,110,926.40. This represents a 85.71% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 61,694 shares of company stock worth $1,664,818 and have sold 97,976 shares worth $4,391,729. Company insiders own 12.48% of the company's stock.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.